Abstract: The present disclosure provides a process for removing fluoroorganic acidic compounds from a solution comprising at least one protic solvent, comprising: forming a mixture of a solution comprising at least one fluoroorganic acidic compound comprising less than 15 carbon atoms and protic solvent, wherein the solution has a pH of 4, with an extraction composition comprising at least one trialkylamine and organic solvent; reacting the fluoroorganic acidic compound with the trialkylamine to form a hydrophobic ionic compound comprising the anion of the fluoroorganic acidic compound and the cation of the trialkylamine; separating the mixture into a first phase comprising the protic solvent and at most 50 wt.

Abstract: The present disclosure provides a process for removing fluoroorganic acidic compounds from a dispersion of fluoroorganic polymer particles in at least one protic solvent, the process comprising the following steps: (i) forming a mixture of a. a dispersion having a pH-value of less than 6 and comprising fluoroorganic polymer particles, at least one protic solvent and at least one fluoroorganic acidic compound with b.

Abstract: Embodiments in the present description provide an operation request processing method and apparatus, and a device, and a readable storage medium, and a system. In the present embodiment, after obtaining an operation request for a data table, a read-write node can return a request processing completion message to a requester in time without waiting for all read-only nodes; a locking operation is performed on the data table, a log of locking the data table is written into a redo log file; and after status information of the log of locking is written into a status record, a monitoring processing process can achieve log playback monitoring of all the read-only nodes by using the status record and the log of locking. Thus, an asynchronous processing mechanism is achieved, and the stability and efficiency of operation request execution are improved.

Abstract: Embodiments of this application disclose a method for processing a floating point number and a related device, which may be used in the fields of general-purpose computing, high performance computing, artificial intelligence training and inference, and the like. The method includes: obtaining a first floating point number, where the first floating point number includes a first sign field, an exponent bit width field, a first exponent field, and a first mantissa field, and the exponent bit width field is used for indicating a bit width D occupied by the first exponent field in a total bit width N of the first floating point number; and obtaining normalized data corresponding to the first floating point number based on the first sign field, the exponent bit width field, the first exponent field, and the first mantissa field.

Abstract: The present disclosure provides a process for removing fluoroorganic acidic compounds from an emulsion of fluoroorganic polymer particles, the process comprising the following steps: (i) forming a mixture of a. an emulsion comprising fluoroorganic polymer particles, at least one fluoroorganic acidic compound and at least one protic solvent, with b.

Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PDL 1 and PD-L 1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

Abstract: According to the present disclosure, a method of fabricating a metal-carbon fibrous structure is provided. The method comprises the steps of: (a) forming a fibrous support structure comprising composite nanocrystals and polymeric fibers, wherein each of the composite nanocrystals comprises metal ions connected by organic ligands; (b) growing the composite nanocrystals on the fibrous support structure; and (c) subjecting the fibrous support structure of step (b) to carbonization to form the metal-carbon fibrous structure, wherein the metal-carbon fibrous structure comprises metal nanoparticles derived from the composite nanocrystals. A metal-carbon fibrous structure comprising carbon based fibers arranged to form a porous network and the carbon based fibers are doped with metal nanoparticles, wherein the carbon based fibers have surfaces which comprise graphitic carbon, is also disclosed herein.

Abstract: In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.

Abstract: In accordance with the present disclosure, macrocyclic compounds of formula (I) have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.

Abstract: In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.

Abstract: In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.

Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.

Abstract: According to the present disclosure, a method of fabricating a metal-carbon fibrous structure is provided. The method comprises the steps of: (a) forming a fibrous support structure comprising composite nanocrystals and polymeric fibers, wherein each of the composite nanocrystals comprises metal ions connected by organic ligands; (b) growing the composite nanocrystals on the fibrous support structure; and (c) subjecting the fibrous support structure of step (b) to carbonization to form the metal-carbon fibrous structure, wherein the metal-carbon fibrous structure comprises metal nanoparticles derived from the composite nanocrystals. A metal-carbon fibrous structure comprising carbon based fibers arranged to form a porous network and the carbon based fibers are doped with metal nanoparticles, wherein the carbon based fibers have surfaces which comprise graphitic carbon, is also disclosed herein.

Abstract: According to the present disclosure, a method of fabricating a metal-carbon fibrous structure is provided. The method comprises the steps of: (a) forming a fibrous support structure comprising composite nanocrystals and polymeric fibers, wherein each of the composite nanocrystals comprises metal ions connected by organic ligands; (b) growing the composite nanocrystals on the fibrous support structure; and (c) subjecting the fibrous support structure of step (b) to carbonization to form the metal-carbon fibrous structure, wherein the metal-carbon fibrous structure comprises metal nanoparticles derived from the composite nanocrystals comprising metal organic framework (MOF), particularly zeolitic imidazolate framework (ZIF). A metal-carbon fibrous structure comprising carbon based fibers arranged to form a porous network and the carbon based fibers are doped with metal nanoparticles, wherein the carbon based fibers have surfaces which comprise graphitic carbon, is also disclosed herein.

Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, ?2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.

Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.

Abstract: A composition includes a hydrofluoroepoxide having Structural Formula (I). Each Rf is, independently, a linear or branched perfluoroalkyl group having 1-6 carbon atoms and optionally comprises a catenated heteroatom.

Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.

Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.

Abstract: Described herein is a partially fluorinated copolymer of the formula: (I); wherein R1 is selected from F or a fluorinated methyl; R2 is selected from H, F, a methyl, or a (per)fluorinated methyl; R3? is a linear or branched fluorinated alkyl group comprising 1 to 12 carbon atoms, optionally with at least one catenated oxygen atom; p is 0, 1, or 2; r is 0 or 1; and Q comprises at least one of an hydroxide, a nitrile, an ester, a silane, a siloxane, a phosphoric acid or salt thereof, a sulphuric acid or salt thereof, an alkyl, an aryl, and combinations thereof; n is an integer of at least 2; and m is an integer of at least 2.